BCYC News and Press, Bicycle Therapeutics plc From 01/04/23

Clinical-stage biotech Bicycle Therapeutics ( NASDAQ: BCYC ) jumped ~10% pre-market Wednesday after announcing that the FDA granted Fast Track Designation for its experimental bladder cancer therapy BT8009. Specifically, the FDA has issued the Fast Track Designation for BT8009 as ...

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle ® ) technology, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track ...

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that preclinical data for BT7480, a novel Bicycle tumor-targ...

The Phase II multi-center, open label trial will evaluate BT8009 administered at the recommended Phase II doses of 5mg/m 2 and 7.5mg/m 2 Phase I dose escalation cohorts complete; results to be presented at a medical conference in 1H 2023 Confirmed RECIST re...

Bicycle Therapeutics press release ( NASDAQ: BCYC ): Q3 GAAP EPS of -$0.96 misses by $0.05 . Revenue of $3.04M (-29.8% Y/Y) misses by $2.54M . Cash and cash equivalents of $361.5 million as of September 30, 2022; expected financial runway into 2025 Re...

- Continued clinical progress across pipeline including BT5528 end of Phase I dose escalation update; completion of enrollment in BT5528 initial dose expansion cohorts expected in Q4 - BT8009 clinical update remains on-track for Q4 - Received $10 millio...

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that an article highlighting preclinical data from BT8009, a Nec...

Summary Today, we take our first look at Bicycle Therapeutics, a small developmental biotech concern. The company has some intriguing early stage drug candidates, is well funded and has a couple of partnerships with much larger drug companies. An analysis follows in the paragr...

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that an article highlighting preclinical data from BT8009, a Nec...

Anti-tumor activity observed in heavily pre-treated patients with EphA2-positive ovarian and urothelial cancers ; overall response rates of 22% (including one complete response) and 67%, respectively Emergent safety profile of BT5528 suggests notable differentiation from c...